Helios Cardio

Executive Summary

Helios Cardio is a private biotechnology company founded in 2016, focused on cardiac repair and regeneration using its proprietary Fetal Engineered Biologic Matrix (f-EBM) platform. The company’s technology creates a cell-friendly biologic tissue scaffold designed to promote reconstruction and healing in challenging cardiovascular conditions, including chronic heart failure and complications from open-heart surgery. By mimicking the regenerative properties of fetal tissue, f-EBM aims to address significant unmet needs where current treatments are limited. The company is based in Boston, formerly San Francisco, and has not yet disclosed total funding or valuation, suggesting an early-stage profile with potential for growth. The platform’s differentiation lies in its biologic composition and targeted application to cardiac repair, a market with high patient demand and limited innovation. As Helios Cardio progresses toward clinical development, its success depends on manufacturing scalability, regulatory pathway navigation, and securing additional capital. The company’s focus on regenerative biologics places it in a competitive but promising space within cardiovascular therapeutics.

Upcoming Catalysts (preview)

• Q4 2026Initiation of First-in-Human Phase 1 Trial for f-EBM in Heart Failure45% success
• Q2 2026Series B Financing Round to Support Clinical Development65% success
• 2027Strategic Partnership with a Major Cardiovascular Firm30% success